Rapacuronium bromide (brand name Raplon) is a rapidly acting, non-depolarizing aminosteroid

neuromuscular blocker Neuromuscular-blocking drugs block neuromuscular transmission at the neuromuscular junction, causing paralysis of the affected skeletal muscles. This is accomplished via their action on the post-synaptic acetylcholine (Nm) receptors. In clin ...

formerly used in modern anaesthesia, to aid and enable endotracheal intubation, which is often necessary to assist in the controlled ventilation of unconscious patients during surgery and sometimes in intensive care. As a non-depolarizing agent it did not cause initial stimulation of muscles before weakening them. Due to risk of fatal bronchospasm it was withdrawn from the United States market by Organon on March 27, 2001, less than 2 years after its FDA approval in 1999.

References

Muscle relaxants Nicotinic antagonists Withdrawn drugs Quaternary ammonium compounds 1-Piperidinyl compounds Acetate esters Propionate esters Androstanes Neuromuscular blockers {{musculoskeletal-drug-stub